Fig. 6

Relationship between serum miR-130a-3p concentration and progression-free survival of patients with NSCLC treated with osimertinib (a) Relative serum miR-130a-3p concentrations in patients with NSCLC. The miR-130a-3p expression indicates the values calculated using the 2−ΔΔCT method and normalized using U6 levels. (b) Progression-free survival of patients with NSCLC treated with first-line osimertinib. Arrows indicate ongoing treatment. * transfer to different institution; # death; AE, discontinuation of treatment due to adverse event; PD, progressive disease; NSCLC, non-small-cell lung cancer.